Candidate Plasma Biomarkers to Detect Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors: A Case Control Study in the Dutch Childhood Cancer Survivor Study

Background Plasma biomarkers may aid in the detection of anthracycline-related cardiomyopathy (ACMP). However, the currently available biomarkers have limited diagnostic value in long-term childhood cancer survivors. This study sought to identify diagnostic plasma biomarkers for ACMP in childhood cancer survivors. Methods and Results We measured 275 plasma proteins in 28 ACMP cases with left ventricular ejection fraction <45%, 29 anthracycline-treated controls with left ventricular ejection fraction ≥53% matched on sex, time after cancer, and anthracycline dose, and 29 patients with genetic... Mehr ...

Verfasser: Leerink, Jan M
Feijen, Elizabeth A M
Moerland, Perry D
de Baat, Esmee C
Merkx, Remy
van der Pal, Helena J H
Tissing, Wim J E
Louwerens, Marloes
van den Heuvel-Eibrink, Marry M
Versluys, A Birgitta
Asselbergs, Folkert W
Sammani, Arjan
Teske, Arco J
van Dalen, Elvira C
van der Heiden-van der Loo, Margriet
van Dulmen-den Broeder, Eline
de Vries, Andrica C H
Kapusta, Livia
Loonen, Jacqueline
Pinto, Yigal M
Kremer, Leontien C M
Mavinkurve-Groothuis, Annelies M C
Kok, Wouter E M
Dokumenttyp: Artikel
Erscheinungsdatum: 2022
Schlagwörter: anthracycline-related cardiomyopathy / biomarkers / cancer therapy-related cardiac dysfunction / cardio-oncology / chemokine ligands / childhood cancer survivors / Cardiology and Cardiovascular Medicine
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29040441
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://dspace.library.uu.nl/handle/1874/450616